AAA
BBIO icon

Affinity Asset Advisors’s BridgeBio Pharma BBIO Stock Holding History

Affinity Asset Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-250,000
Closed -$7.73M – 104
2024
Q1 		$7.73M Buy
+250,000
New +$8.5M 0.96% 34

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Affinity Asset Advisors's BBIO Position: Q1 2026 in Review

Affinity Asset Advisors reduced its BridgeBio Pharma (BBIO) stake by 53% in Q1 2026, selling an estimated $12.3M and leaving 150,000 shares worth $11.1M. The position accounts for 0.58% of the portfolio, ranked #45.

Affinity Asset Advisors first reported a position in BBIO in Q4 2020 and has held it in 18 quarters since. The position peaked at $35.6M in Q1 2021. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Affinity Asset Advisors held 150,000 shares of BridgeBio Pharma worth $11.1M as of Q1 2026.
  • Affinity Asset Advisors sold 170,000 BridgeBio Pharma shares in Q1 2026, an estimated $12.3M.
  • BridgeBio Pharma made up 0.58% of Affinity Asset Advisors's portfolio in Q1 2026, its #45 holding.
  • Affinity Asset Advisors first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 18 quarters since.
  • Affinity Asset Advisors's BridgeBio Pharma position peaked at $35.6M in Q1 2021.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.